CytomX Therapeutics Management
Management Kriterienprüfungen 3/4
CytomX Therapeutics' CEO ist Sean McCarthy , ernannt in Aug 2011, hat eine Amtszeit von 12.83 Jahren. Die jährliche Gesamtvergütung beträgt $2.61M , bestehend aus 25% Gehalt und 75% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.68% der Aktien des Unternehmens, im Wert von $725.97K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.2 Jahre bzw. 4.4 Jahre.
Wichtige Informationen
Sean McCarthy
Geschäftsführender
US$2.6m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 25.0% |
Amtszeit als Geschäftsführer | 12.8yrs |
Eigentum des Geschäftsführers | 0.7% |
Durchschnittliche Amtszeit des Managements | 3.2yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.4yrs |
Jüngste Management Updates
Recent updates
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$17m |
Dec 31 2023 | US$3m | US$652k | -US$569k |
Sep 30 2023 | n/a | n/a | -US$10m |
Jun 30 2023 | n/a | n/a | -US$42m |
Mar 31 2023 | n/a | n/a | -US$71m |
Dec 31 2022 | US$3m | US$623k | -US$99m |
Sep 30 2022 | n/a | n/a | -US$149m |
Jun 30 2022 | n/a | n/a | -US$143m |
Mar 31 2022 | n/a | n/a | -US$132m |
Dec 31 2021 | US$4m | US$616k | -US$116m |
Sep 30 2021 | n/a | n/a | -US$72m |
Jun 30 2021 | n/a | n/a | -US$64m |
Mar 31 2021 | n/a | n/a | -US$61m |
Dec 31 2020 | US$3m | US$595k | -US$65m |
Sep 30 2020 | n/a | n/a | -US$54m |
Jun 30 2020 | n/a | n/a | -US$63m |
Mar 31 2020 | n/a | n/a | -US$76m |
Dec 31 2019 | US$4m | US$575k | -US$133m |
Sep 30 2019 | n/a | n/a | -US$99m |
Jun 30 2019 | n/a | n/a | -US$99m |
Mar 31 2019 | n/a | n/a | -US$83m |
Dec 31 2018 | US$5m | US$550k | -US$85m |
Sep 30 2018 | n/a | n/a | -US$52m |
Jun 30 2018 | n/a | n/a | -US$39m |
Mar 31 2018 | n/a | n/a | -US$50m |
Dec 31 2017 | US$3m | US$500k | -US$43m |
Vergütung im Vergleich zum Markt: SeanDie Gesamtvergütung ($USD2.61M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).
Entschädigung vs. Einkommen: SeanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sean McCarthy (57 yo)
12.8yrs
Amtszeit
US$2,611,138
Vergütung
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Chairman & CEO | 12.8yrs | US$2.61m | 0.68% $ 641.2k | |
Senior VP & Chief Scientific Officer | 1.4yrs | US$1.21m | 0.076% $ 71.9k | |
Senior VP | 3.2yrs | US$1.05m | 0.068% $ 64.1k | |
Chief Financial Officer | 1.8yrs | keine Daten | 0.033% $ 30.7k | |
Senior VP | 6.1yrs | US$1.21m | 0.083% $ 78.4k | |
Senior VP & Chief Human Resources Officer | no data | keine Daten | keine Daten | |
Senior Vice President of Intellectual Property | 5.3yrs | keine Daten | keine Daten | |
Chief Medical Officer | less than a year | keine Daten | keine Daten | |
Senior Vice President of Quality & Product Manufacturing | 1.4yrs | keine Daten | keine Daten | |
Special Advisor to Chief Executive Officer | no data | US$273.54k | keine Daten |
3.2yrs
Durchschnittliche Betriebszugehörigkeit
55.5yo
Durchschnittliches Alter
Erfahrenes Management: CTMXDas Führungsteam des Unternehmens gilt als erfahren (3.2 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Chairman & CEO | 12.8yrs | US$2.61m | 0.68% $ 641.2k | |
Independent Director | 5.1yrs | US$75.12k | 0.0066% $ 6.2k | |
Member of Scientific Advisory Board | 4.4yrs | keine Daten | keine Daten | |
Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
Independent Director | 3.5yrs | US$78.62k | 0% $ 0 | |
Independent Director | 5.5yrs | US$77.12k | 0% $ 0 | |
Lead Independent Director | 8.8yrs | US$105.12k | 0% $ 0 | |
Independent Director | 4.2yrs | US$80.62k | 0% $ 0 | |
Member of Scientific Advisory Board | 3.5yrs | US$8.03m | keine Daten | |
Independent Director | 2.8yrs | US$69.12k | 0% $ 0 | |
Member of Scientific Advisory Board | 4.4yrs | keine Daten | keine Daten | |
Member of Scientific Advisory Board | 1.4yrs | keine Daten | keine Daten |
4.4yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: CTMXDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).